Literature DB >> 16926059

Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles.

M Laird Forrest1, Anni Zhao, Chee-Youb Won, A Waseem Malick, Glen S Kwon.   

Abstract

A solvent and Cremephor free formulation of the anticancer chemotherapeutic geldanamycin was prepared using amphiphilic block co-polymer micelles of poly(ethylene glycol)-b-poly(epsilon-caprolactone) (PEG-b-PCL). Although geldanamycin was not solubilized by PEG-b-PCL micelles, fatty acid prodrugs of geldanamycin were encapsulated in PEG-b-PCL micelles by a co-solvent extraction technique. Resulting PEG-b-PCL micelles were <120 nm in diameter and solubilized >20% w/w geldanamycin prodrugs increasing aqueous solubility to >2 mg/mL. PEG-b-PCL micelles released the geldanamycin prodrugs over several days, t(1/2) 2.2 to 9.6 days. The free prodrugs hydrolyzed rapidly, t(1/2)<6 h, into the geldanamycin analogue 17-beta-hydroxyethylamino-17-demethoxygeldanamycin, which has high activity against MCF-7 breast cancer cells, IC(50) 240 nM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926059     DOI: 10.1016/j.jconrel.2006.07.003

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  18 in total

1.  Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.

Authors:  Ruibao Chen; Yunqi Zhao; Yan Huang; Qiuhong Yang; Xing Zeng; Wencong Jiang; Jihong Liu; J Brantley Thrasher; M Laird Forrest; Benyi Li
Journal:  Prostate       Date:  2015-01-25       Impact factor: 4.104

2.  Controlled block copolymer micelle formation for encapsulation of hydrophobic ingredients.

Authors:  Jérôme G J L Lebouille; Leo F W Vleugels; Aylvin A Dias; Frans A M Leermakers; Martien A Cohen Stuart; Remco Tuinier
Journal:  Eur Phys J E Soft Matter       Date:  2013-09-26       Impact factor: 1.890

3.  Mixed pH-sensitive polymeric micelles for combination drug delivery.

Authors:  Younsoo Bae; Adam W G Alani; Nicole C Rockich; T S Z Chung Lai; Glen S Kwon
Journal:  Pharm Res       Date:  2010-08-11       Impact factor: 4.200

4.  Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats.

Authors:  May P Xiong; Jaime A Yáñez; Connie M Remsberg; Yusuke Ohgami; Glen S Kwon; Neal M Davies; M Laird Forrest
Journal:  J Control Release       Date:  2008-03-25       Impact factor: 9.776

Review 5.  Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.

Authors:  Duhyeong Hwang; Jacob D Ramsey; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2020-09-24       Impact factor: 15.470

6.  Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity.

Authors:  M Laird Forrest; Jaime A Yáñez; Connie M Remsberg; Yusuke Ohgami; Glen S Kwon; Neal M Davies
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

Review 7.  Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery.

Authors:  Lilian E van Vlerken; Tushar K Vyas; Mansoor M Amiji
Journal:  Pharm Res       Date:  2007-03-29       Impact factor: 4.200

Review 8.  Nanoparticle-mediated drug delivery for treating melanoma.

Authors:  Vaibhav Mundra; Wei Li; Ram I Mahato
Journal:  Nanomedicine (Lond)       Date:  2015-08-05       Impact factor: 5.307

9.  Noninvasive fluorescence resonance energy transfer imaging of in vivo premature drug release from polymeric nanoparticles.

Authors:  Peng Zou; Hongwei Chen; Hayley J Paholak; Duxin Sun
Journal:  Mol Pharm       Date:  2013-10-14       Impact factor: 4.939

10.  A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats.

Authors:  May P Xiong; Jaime A Yáñez; Glen S Kwon; Neal M Davies; M Laird Forrest
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.